Picture Sino Biological Symposium Antibody Engineering Leipzig 650x100px
Document › Details

Alzinova AB. (1/24/23). "Press Release: Alzinova Recruits Business Development Director".

Organisation Organisation Alzinova AB (publ)
Products Product ALZ-101 (Alzinova)
  Product 2 ALZ-201 (Alzinova)
Persons Person Hansson, Sebastian (Alzinova– 202301 Business Development Director before SWIPP)
  Person 2 Torfgård, Kristina (Alzinova 202301 CEO)

Alzinova AB (publ) (“Alzinova” or the “Company”) is pleased to announce that the Company has strengthened its management team by appointing Sebastian Hansson as the new Business Development Director. In this newly created role, Sebastian will be instrumental in driving the strategic and operational work within Business Development for Alzinova.

Alzinova appoints Sebastian Hansson as new Business Development Director with responsibility for the continued business development that runs parallel to the further development of the Company's drug candidates ALZ-101 and ALZ-201. Sebastian holds a PhD in molecular biophysics and an MBA. He has 15 years of experience in drug development, CRO and GMP production of pharmaceutical compounds. Sebastian comes most recently from a position as Chief Operating Officer, COO at SWIPP.

“I am very pleased to appoint Sebastian Hansson as the new Business Development Director for Alzinova. Sebastian will be a valuable asset to our management team and in driving the strategic and operational work within Business Development. Sebastian brings many years of solid experience in the pharmaceutical industry, most recently as COO at SWIPP”, says Kristina Torfgård, CEO of Alzinova.

“I am delighted to have been entrusted to lead the business development of Alzinova - an exciting company with great potential to become a leading player in the development of treatments for Alzheimer's disease. I look forward to top-line data from the ongoing clinical trial and using this to drive value and interest from potential partners. This in turn will allow us to build the Company further and develop our partnering activities", says Sebastian Hansson, Business Development Director for Alzinova.

For more information, please contact:

Kristina Torfgård, CEO
Tel. +46 708 46 79 75

Please note that this is an English translation of a press release written in Swedish by Alzinova AB (publ), in the event of any inaccuracies, the Swedish version applies.

About Alzinova

Alzinova AB is a Swedish clinical-stage biopharma company specializing in the treatment of Alzheimer’s disease targeting toxic amyloid beta oligomers. The lead candidate, ALZ-101, is being developed as a therapeutic vaccine for the treatment of Alzheimer's. Alzinova’s proprietary AßCC peptide™ technology enables the development of disease-modifying treatments that target the toxic amyloid beta oligomers involved in the onset and progression of the disease with high precision. Alzheimer’s is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in preclinical development, and the ambition is to expand the pipeline further. The company’s Certified Adviser on Nasdaq First North Growth Market is Redeye AB. For more information about Alzinova, please visit:

Record changed: 2024-01-20


Picture EBD Group World of Partnering Opportunities 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture Sino Biological Symposium Antibody Engineering Leipzig 650x200px

» top